263 related articles for article (PubMed ID: 21608333)
21. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
22. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Katz G; Zehavi C; Treister G
Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
[TBL] [Abstract][Full Text] [Related]
23. Eliminating antibiotic prophylaxis for intravitreal injections: a consecutive series of 18,839 injections by a single surgeon.
Bhavsar AR; Sandler DR
Retina; 2015 Apr; 35(4):783-8. PubMed ID: 25526099
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
25. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
[TBL] [Abstract][Full Text] [Related]
27. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
29. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
[TBL] [Abstract][Full Text] [Related]
31. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection.
Chong DY; Anand R; Williams PD; Qureshi JA; Callanan DG
Retina; 2010 Oct; 30(9):1432-40. PubMed ID: 20559156
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab and retinal vein occlusion. Too many outstanding questions.
Prescrire Int; 2012 Sep; 21(130):207. PubMed ID: 23016250
[TBL] [Abstract][Full Text] [Related]
34. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for branch retinal vein occlusion.
Spandau U; Wickenhäuser A; Rensch F; Jonas J
Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
[No Abstract] [Full Text] [Related]
36. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
37. The treatment of branch retinal vein occlusion with bevacizumab.
Badalà F
Curr Opin Ophthalmol; 2008 May; 19(3):234-8. PubMed ID: 18408499
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms.
Pichi F; Morara M; Torrazza C; Manzi G; Alkabes M; Balducci N; Vitale L; Lembo A; Ciardella AP; Nucci P
Am J Ophthalmol; 2013 Feb; 155(2):287-294.e1. PubMed ID: 23111179
[TBL] [Abstract][Full Text] [Related]
39. [Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration].
Kloos P; Niederberger H; Valmaggia C
Klin Monbl Augenheilkd; 2011 Apr; 228(4):340-4. PubMed ID: 21484643
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]